MCL Treatment Advances and Future Directions
Martin Dreyling, MD, spoke about the potential use of CAR T-cell therapy in earlier treatment stages for certain patient groups with mantle cell lymphoma.
Unraveling Resistance and Heterogeneity in Mantle Cell Lymphoma Management
The Lymphoma Research Foundation MCL Scientific Consortium and Workshop focused on relevant topics that can help clinicians personalize treatment for patients.
Copanlisib Yields Responses in Relapsed/Refractory Non-Hodgkin Lymphoma
This video reviews results of the phase II CHRONOS-1 trial, a single-arm study evaluating the investigational agent copanlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
2 Commerce Drive Cranbury, NJ 08512